SallyHeng personal page - To The Moon

SallyHeng

SallyHeng

No personal profile

2Follow

0Followers

0Topic

0Badge

2024-06-30

Happy 10th Anniversary!

2021-06-28

Good

Sorry, the original content has been removed

2021-06-24

Hmmm

Sorry, the original content has been removed

2021-06-24

Hmmm

Sorry, the original content has been removed

2021-06-24

Hmmmm

Sorry, the original content has been removed

2021-06-23

Ok

Sorry, the original content has been removed

2021-06-23

Bad new.

Sorry, the original content has been removed

2021-06-21

Oic

Sorry, the original content has been removed

2021-06-21

Oic

Orphazyme rose more than 6% in premarket trading

2021-06-20

Noted

Sorry, the original content has been removed

2021-06-20

?

How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free

2021-06-17

Noted.

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586392753235214","uuid":"3586392753235214","gmtCreate":1623304361407,"gmtModify":1638287815048,"name":"SallyHeng","pinyin":"sallyheng","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","hat":"https://static.tigerbbs.com/646756f1284a5a6480ed02cc4fa7d1d2","hatId":"ca_profile_frame_PjQGBT","hatName":"LV6 头像框","vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.16","exceedPercentage":"80.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.19","exceedPercentage":"60.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":322358265249872,"gmtCreate":1719731224179,"gmtModify":1719731228681,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Happy 10th Anniversary!","listText":"Happy 10th Anniversary!","text":"Happy 10th Anniversary!","images":[{"img":"https://community-static.tradeup.com/news/c896ed999e31303f90c6d28012aa5134"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322358265249872","isVote":1,"tweetType":1,"viewCount":1650,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127937954,"gmtCreate":1624812208778,"gmtModify":1703845470869,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/127937954","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":1881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121277894,"gmtCreate":1624468886918,"gmtModify":1703837777693,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121277894","repostId":"2145018083","repostType":2,"isVote":1,"tweetType":1,"viewCount":1932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121274852,"gmtCreate":1624468783076,"gmtModify":1703837777046,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121274852","repostId":"2145531099","repostType":4,"isVote":1,"tweetType":1,"viewCount":1532,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121274053,"gmtCreate":1624468759172,"gmtModify":1703837776398,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121274053","repostId":"2145531099","repostType":4,"isVote":1,"tweetType":1,"viewCount":1711,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123565383,"gmtCreate":1624430035242,"gmtModify":1703836449796,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123565383","repostId":"2145060923","repostType":2,"isVote":1,"tweetType":1,"viewCount":1786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123587797,"gmtCreate":1624429670919,"gmtModify":1703836439468,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Bad new.","listText":"Bad new.","text":"Bad new.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/123587797","repostId":"2145520610","repostType":4,"isVote":1,"tweetType":1,"viewCount":2464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167298264,"gmtCreate":1624268874158,"gmtModify":1703832012888,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Oic","listText":"Oic","text":"Oic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167298264","repostId":"1172678753","repostType":4,"isVote":1,"tweetType":1,"viewCount":2047,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167293257,"gmtCreate":1624268734479,"gmtModify":1703832009767,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Oic","listText":"Oic","text":"Oic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167293257","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=en_US&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":2037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164033269,"gmtCreate":1624160897051,"gmtModify":1703829821427,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164033269","repostId":"1126454279","repostType":2,"isVote":1,"tweetType":1,"viewCount":1281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164097393,"gmtCreate":1624160753612,"gmtModify":1703829817204,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164097393","repostId":"2144706496","repostType":2,"repost":{"id":"2144706496","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1624147740,"share":"https://ttm.financial/m/news/2144706496?lang=en_US&edition=fundamental","pubTime":"2021-06-20 08:09","market":"us","language":"en","title":"How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free","url":"https://stock-news.laohu8.com/highlight/detail?id=2144706496","media":"Dow Jones","summary":"MW How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n\n\n  Catey H","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n</p>\n<p>\n  Catey Hill \n</p>\n<p>\n  Even after the free trial ends, Amazon Music Unlimited is cheaper for Prime members than Spotify or Tidal. Should you try it? \n</p>\n<p>\n  MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive. \n</p>\n<p>\n  This deal may be music to your ears: Amazon has announced that it is now offering a four-month free trial of its Amazon Music Unlimited service  Should you give it a try? \n</p>\n<p>\n  What we like about the deal: With Amazon Music Unlimited, you get ad-free, unlimited access to 75 million songs in HD, everything from classics like the entire Beatles catalog to newer hitmakers like Bruno Mars. You will also have access to thousands of curated playlists and stations, as well as podcasts, and can listen to any song, anytime and anywhere. Note that this is different than Prime Music, which Prime members get for free, but only has about 2 million songs. \n</p>\n<p>\n  Critics speak highly of the service, with PC Magazine , than Spotify or Tidal, though non-Prime members pay $9.99 per month. You can cancel renewal any time by visiting your Amazon Music Settings. \n</p>\n<p>\n  Other things to consider: Tidal and Spotify tend to have more bells and whistles, some reviewers note, and Prime members already get two million songs free, which might be enough for very casual music listeners. You also will need to remember to cancel if you don't like the service; and this deal is only available to Prime members who have not already tried Amazon Music Unlimited.Bottom line: If you're looking for a streaming service, this could be worth a try for those considering a new music subscription service. If you're a Prime member, the $7.99 price tag is especially enticing. \n</p>\n<p>\n  FREE TRIAL: Get 4 months of Amazon Music Unlimited free  \n</p>\n<p>\n  -Catey Hill; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 19, 2021 20:09 ET (00:09 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-20 08:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n</p>\n<p>\n  Catey Hill \n</p>\n<p>\n  Even after the free trial ends, Amazon Music Unlimited is cheaper for Prime members than Spotify or Tidal. Should you try it? \n</p>\n<p>\n  MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive. \n</p>\n<p>\n  This deal may be music to your ears: Amazon has announced that it is now offering a four-month free trial of its Amazon Music Unlimited service  Should you give it a try? \n</p>\n<p>\n  What we like about the deal: With Amazon Music Unlimited, you get ad-free, unlimited access to 75 million songs in HD, everything from classics like the entire Beatles catalog to newer hitmakers like Bruno Mars. You will also have access to thousands of curated playlists and stations, as well as podcasts, and can listen to any song, anytime and anywhere. Note that this is different than Prime Music, which Prime members get for free, but only has about 2 million songs. \n</p>\n<p>\n  Critics speak highly of the service, with PC Magazine , than Spotify or Tidal, though non-Prime members pay $9.99 per month. You can cancel renewal any time by visiting your Amazon Music Settings. \n</p>\n<p>\n  Other things to consider: Tidal and Spotify tend to have more bells and whistles, some reviewers note, and Prime members already get two million songs free, which might be enough for very casual music listeners. You also will need to remember to cancel if you don't like the service; and this deal is only available to Prime members who have not already tried Amazon Music Unlimited.Bottom line: If you're looking for a streaming service, this could be worth a try for those considering a new music subscription service. If you're a Prime member, the $7.99 price tag is especially enticing. \n</p>\n<p>\n  FREE TRIAL: Get 4 months of Amazon Music Unlimited free  \n</p>\n<p>\n  -Catey Hill; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 19, 2021 20:09 ET (00:09 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QNETCN":"纳斯达克中美互联网老虎指数","03086":"华夏纳指","09086":"华夏纳指-U","AMZN":"亚马逊"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144706496","content_text":"MW How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n\n\n  Catey Hill \n\n\n  Even after the free trial ends, Amazon Music Unlimited is cheaper for Prime members than Spotify or Tidal. Should you try it? \n\n\n  MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive. \n\n\n  This deal may be music to your ears: Amazon has announced that it is now offering a four-month free trial of its Amazon Music Unlimited service  Should you give it a try? \n\n\n  What we like about the deal: With Amazon Music Unlimited, you get ad-free, unlimited access to 75 million songs in HD, everything from classics like the entire Beatles catalog to newer hitmakers like Bruno Mars. You will also have access to thousands of curated playlists and stations, as well as podcasts, and can listen to any song, anytime and anywhere. Note that this is different than Prime Music, which Prime members get for free, but only has about 2 million songs. \n\n\n  Critics speak highly of the service, with PC Magazine , than Spotify or Tidal, though non-Prime members pay $9.99 per month. You can cancel renewal any time by visiting your Amazon Music Settings. \n\n\n  Other things to consider: Tidal and Spotify tend to have more bells and whistles, some reviewers note, and Prime members already get two million songs free, which might be enough for very casual music listeners. You also will need to remember to cancel if you don't like the service; and this deal is only available to Prime members who have not already tried Amazon Music Unlimited.Bottom line: If you're looking for a streaming service, this could be worth a try for those considering a new music subscription service. If you're a Prime member, the $7.99 price tag is especially enticing. \n\n\n  FREE TRIAL: Get 4 months of Amazon Music Unlimited free  \n\n\n  -Catey Hill; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  June 19, 2021 20:09 ET (00:09 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"03086":0.6,"09086":0.6,"AMZN":0.9,"QNETCN":0.6}},"isVote":1,"tweetType":1,"viewCount":658,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168017197,"gmtCreate":1623943740919,"gmtModify":1703824279721,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Noted.","listText":"Noted.","text":"Noted.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168017197","repostId":"1108846547","repostType":4,"isVote":1,"tweetType":1,"viewCount":830,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":167298264,"gmtCreate":1624268874158,"gmtModify":1703832012888,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Oic","listText":"Oic","text":"Oic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167298264","repostId":"1172678753","repostType":4,"isVote":1,"tweetType":1,"viewCount":2047,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127937954,"gmtCreate":1624812208778,"gmtModify":1703845470869,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/127937954","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":1881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123587797,"gmtCreate":1624429670919,"gmtModify":1703836439468,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Bad new.","listText":"Bad new.","text":"Bad new.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/123587797","repostId":"2145520610","repostType":4,"isVote":1,"tweetType":1,"viewCount":2464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164033269,"gmtCreate":1624160897051,"gmtModify":1703829821427,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164033269","repostId":"1126454279","repostType":2,"isVote":1,"tweetType":1,"viewCount":1281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121274852,"gmtCreate":1624468783076,"gmtModify":1703837777046,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121274852","repostId":"2145531099","repostType":4,"isVote":1,"tweetType":1,"viewCount":1532,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164097393,"gmtCreate":1624160753612,"gmtModify":1703829817204,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164097393","repostId":"2144706496","repostType":2,"repost":{"id":"2144706496","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1624147740,"share":"https://ttm.financial/m/news/2144706496?lang=en_US&edition=fundamental","pubTime":"2021-06-20 08:09","market":"us","language":"en","title":"How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free","url":"https://stock-news.laohu8.com/highlight/detail?id=2144706496","media":"Dow Jones","summary":"MW How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n\n\n  Catey H","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n</p>\n<p>\n  Catey Hill \n</p>\n<p>\n  Even after the free trial ends, Amazon Music Unlimited is cheaper for Prime members than Spotify or Tidal. Should you try it? \n</p>\n<p>\n  MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive. \n</p>\n<p>\n  This deal may be music to your ears: Amazon has announced that it is now offering a four-month free trial of its Amazon Music Unlimited service  Should you give it a try? \n</p>\n<p>\n  What we like about the deal: With Amazon Music Unlimited, you get ad-free, unlimited access to 75 million songs in HD, everything from classics like the entire Beatles catalog to newer hitmakers like Bruno Mars. You will also have access to thousands of curated playlists and stations, as well as podcasts, and can listen to any song, anytime and anywhere. Note that this is different than Prime Music, which Prime members get for free, but only has about 2 million songs. \n</p>\n<p>\n  Critics speak highly of the service, with PC Magazine , than Spotify or Tidal, though non-Prime members pay $9.99 per month. You can cancel renewal any time by visiting your Amazon Music Settings. \n</p>\n<p>\n  Other things to consider: Tidal and Spotify tend to have more bells and whistles, some reviewers note, and Prime members already get two million songs free, which might be enough for very casual music listeners. You also will need to remember to cancel if you don't like the service; and this deal is only available to Prime members who have not already tried Amazon Music Unlimited.Bottom line: If you're looking for a streaming service, this could be worth a try for those considering a new music subscription service. If you're a Prime member, the $7.99 price tag is especially enticing. \n</p>\n<p>\n  FREE TRIAL: Get 4 months of Amazon Music Unlimited free  \n</p>\n<p>\n  -Catey Hill; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 19, 2021 20:09 ET (00:09 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-20 08:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n</p>\n<p>\n  Catey Hill \n</p>\n<p>\n  Even after the free trial ends, Amazon Music Unlimited is cheaper for Prime members than Spotify or Tidal. Should you try it? \n</p>\n<p>\n  MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive. \n</p>\n<p>\n  This deal may be music to your ears: Amazon has announced that it is now offering a four-month free trial of its Amazon Music Unlimited service  Should you give it a try? \n</p>\n<p>\n  What we like about the deal: With Amazon Music Unlimited, you get ad-free, unlimited access to 75 million songs in HD, everything from classics like the entire Beatles catalog to newer hitmakers like Bruno Mars. You will also have access to thousands of curated playlists and stations, as well as podcasts, and can listen to any song, anytime and anywhere. Note that this is different than Prime Music, which Prime members get for free, but only has about 2 million songs. \n</p>\n<p>\n  Critics speak highly of the service, with PC Magazine , than Spotify or Tidal, though non-Prime members pay $9.99 per month. You can cancel renewal any time by visiting your Amazon Music Settings. \n</p>\n<p>\n  Other things to consider: Tidal and Spotify tend to have more bells and whistles, some reviewers note, and Prime members already get two million songs free, which might be enough for very casual music listeners. You also will need to remember to cancel if you don't like the service; and this deal is only available to Prime members who have not already tried Amazon Music Unlimited.Bottom line: If you're looking for a streaming service, this could be worth a try for those considering a new music subscription service. If you're a Prime member, the $7.99 price tag is especially enticing. \n</p>\n<p>\n  FREE TRIAL: Get 4 months of Amazon Music Unlimited free  \n</p>\n<p>\n  -Catey Hill; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 19, 2021 20:09 ET (00:09 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QNETCN":"纳斯达克中美互联网老虎指数","03086":"华夏纳指","09086":"华夏纳指-U","AMZN":"亚马逊"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144706496","content_text":"MW How to get 4 months of Amazon's ad-free, 75-million-song streaming music service free\n\n\n  Catey Hill \n\n\n  Even after the free trial ends, Amazon Music Unlimited is cheaper for Prime members than Spotify or Tidal. Should you try it? \n\n\n  MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive. \n\n\n  This deal may be music to your ears: Amazon has announced that it is now offering a four-month free trial of its Amazon Music Unlimited service  Should you give it a try? \n\n\n  What we like about the deal: With Amazon Music Unlimited, you get ad-free, unlimited access to 75 million songs in HD, everything from classics like the entire Beatles catalog to newer hitmakers like Bruno Mars. You will also have access to thousands of curated playlists and stations, as well as podcasts, and can listen to any song, anytime and anywhere. Note that this is different than Prime Music, which Prime members get for free, but only has about 2 million songs. \n\n\n  Critics speak highly of the service, with PC Magazine , than Spotify or Tidal, though non-Prime members pay $9.99 per month. You can cancel renewal any time by visiting your Amazon Music Settings. \n\n\n  Other things to consider: Tidal and Spotify tend to have more bells and whistles, some reviewers note, and Prime members already get two million songs free, which might be enough for very casual music listeners. You also will need to remember to cancel if you don't like the service; and this deal is only available to Prime members who have not already tried Amazon Music Unlimited.Bottom line: If you're looking for a streaming service, this could be worth a try for those considering a new music subscription service. If you're a Prime member, the $7.99 price tag is especially enticing. \n\n\n  FREE TRIAL: Get 4 months of Amazon Music Unlimited free  \n\n\n  -Catey Hill; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  June 19, 2021 20:09 ET (00:09 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"03086":0.6,"09086":0.6,"AMZN":0.9,"QNETCN":0.6}},"isVote":1,"tweetType":1,"viewCount":658,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168017197,"gmtCreate":1623943740919,"gmtModify":1703824279721,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Noted.","listText":"Noted.","text":"Noted.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168017197","repostId":"1108846547","repostType":4,"isVote":1,"tweetType":1,"viewCount":830,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322358265249872,"gmtCreate":1719731224179,"gmtModify":1719731228681,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Happy 10th Anniversary!","listText":"Happy 10th Anniversary!","text":"Happy 10th Anniversary!","images":[{"img":"https://community-static.tradeup.com/news/c896ed999e31303f90c6d28012aa5134"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322358265249872","isVote":1,"tweetType":1,"viewCount":1650,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121277894,"gmtCreate":1624468886918,"gmtModify":1703837777693,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121277894","repostId":"2145018083","repostType":2,"isVote":1,"tweetType":1,"viewCount":1932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121274053,"gmtCreate":1624468759172,"gmtModify":1703837776398,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121274053","repostId":"2145531099","repostType":4,"isVote":1,"tweetType":1,"viewCount":1711,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123565383,"gmtCreate":1624430035242,"gmtModify":1703836449796,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123565383","repostId":"2145060923","repostType":2,"repost":{"id":"2145060923","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624427186,"share":"https://ttm.financial/m/news/2145060923?lang=en_US&edition=fundamental","pubTime":"2021-06-23 13:46","market":"sh","language":"en","title":"LIVE MARKETS-Europe set for muted start","url":"https://stock-news.laohu8.com/highlight/detail?id=2145060923","media":"Reuters","summary":"* European stock futures little changed   * Powell: Fed will not raise rates on inflation fears alon","content":"<html><body><p>* European stock futures little changed</p><p>   * Powell: Fed will not raise rates on inflation fears alone </p><p>   * Asian shares rise</p><p>    June 23 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com</p><p>   EUROPE SET FOR MUTED START (0544 GMT)</p><p>   After two days of gains it looks the post-Fed bounceback is already losing steam in Europe just as the main STOXX 600 regional benchmark remains around 1% below its record peak.</p><p>   Stock futures are pointing to a muted start later on for the cash market with moves ranging between flat and a fall of 0.1%, even as Asia gained overnight and Wall Street was led higher big tech stocks after Powell reaffirmed the Fed's intent not to raise rates too quickly based only on the fear of inflation.</p><p>   June flash PMI surveys will be scrutinised for possible new insight into the strength of the recovery while speeches by ECB's Lagarde and De Guindos are also going to be in focus.</p><p>   (Danilo Masoni) </p><p>   ***** </p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVE MARKETS-Europe set for muted start</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVE MARKETS-Europe set for muted start\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-23 13:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>* European stock futures little changed</p><p>   * Powell: Fed will not raise rates on inflation fears alone </p><p>   * Asian shares rise</p><p>    June 23 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com</p><p>   EUROPE SET FOR MUTED START (0544 GMT)</p><p>   After two days of gains it looks the post-Fed bounceback is already losing steam in Europe just as the main STOXX 600 regional benchmark remains around 1% below its record peak.</p><p>   Stock futures are pointing to a muted start later on for the cash market with moves ranging between flat and a fall of 0.1%, even as Asia gained overnight and Wall Street was led higher big tech stocks after Powell reaffirmed the Fed's intent not to raise rates too quickly based only on the fear of inflation.</p><p>   June flash PMI surveys will be scrutinised for possible new insight into the strength of the recovery while speeches by ECB's Lagarde and De Guindos are also going to be in focus.</p><p>   (Danilo Masoni) </p><p>   ***** </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SDOW":"三倍做空道指30ETF-ProShares","DDM":"2倍做多道指ETF-ProShares","DJX":"1/100道琼斯","DOG":"道指ETF-ProShares做空",".SPX":"S&P 500 Index","DXD":"两倍做空道琼30指数ETF-ProShares",".DJI":"道琼斯","UDOW":"三倍做多道指30ETF-ProShares"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145060923","content_text":"* European stock futures little changed   * Powell: Fed will not raise rates on inflation fears alone    * Asian shares rise    June 23 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com   EUROPE SET FOR MUTED START (0544 GMT)   After two days of gains it looks the post-Fed bounceback is already losing steam in Europe just as the main STOXX 600 regional benchmark remains around 1% below its record peak.   Stock futures are pointing to a muted start later on for the cash market with moves ranging between flat and a fall of 0.1%, even as Asia gained overnight and Wall Street was led higher big tech stocks after Powell reaffirmed the Fed's intent not to raise rates too quickly based only on the fear of inflation.   June flash PMI surveys will be scrutinised for possible new insight into the strength of the recovery while speeches by ECB's Lagarde and De Guindos are also going to be in focus.   (Danilo Masoni)    *****","news_type":1,"symbols_score_info":{"DJX":0.6,"SDOW":0.6,".DJI":0.9,".SPX":0.9,"DDM":0.6,"DOG":0.6,"UDOW":0.6,"DXD":0.6}},"isVote":1,"tweetType":1,"viewCount":1786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167293257,"gmtCreate":1624268734479,"gmtModify":1703832009767,"author":{"id":"3586392753235214","authorId":"3586392753235214","name":"SallyHeng","avatar":"https://static.tigerbbs.com/3661015dde4a13576c22c4ce04b6a1a5","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586392753235214","idStr":"3586392753235214"},"themes":[],"htmlText":"Oic","listText":"Oic","text":"Oic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167293257","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=en_US&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":2037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}